strontium ranelate


Also found in: Wikipedia.

strontium ranelate

A bone-seeking drug shown in the mid-1990s to be capable of substantially reducing the risk of fractures in post-menopausal women with OSTEOPOROSIS. The drug stimulates bone formation and reduces resorption. The usefulness of the drug was shown in a large trial, the results of which were published in January 2004. Side effects are said to be minor.
References in periodicals archive ?
RELATED ARTICLE: Major Finding: During the 5 to 10-year period of extended, continuous treatment with strontium ranelate, postmenopausal women with osteoporosis at baseline had a 21% rate of vertebral fractures and a 14% rate of non- vertebral fractures, significantly less than the 28% and 20% rates, respectively, of fractures in a matched placebo group.
STrontium RAnelate Treatment of OSteoporosis-STRATOS calismasi, postmenopozal vertebral osteoporoz tedavisinde stronsiyum ranelatin minimal etkili dozunu belirlemek amaci ile yapilmistir ve calismanin suresi 2 yil-dir.
Non hormonal - There are several medicines including drugs called bisphosphonates, parathyroid hormone and strontium ranelate.
Strontium ranelate is an interesting compound being investigated in Europe.
When you put them together, they form strontium ranelate, which is a patented drug.
New drugs and treatments are being developed all the time, although some of them are not currently available in the US, such as tibolone and oral strontium ranelate (Protelos).
The study population comprised the placebo groups of two randomized, controlled trials of strontium ranelate.
Your medicine is strontium ranelate (Protelos), a recommended treatment for osteoporosis.
SAN ANTONIO -- The older generation osteoporosis drug, strontium ranelate, is receiving renewed attention as a result of a metaanalysis showing that it reduces fracture rates in postmenopausal women as well as bisphosphonates do.
Strontium ranelate, marketed in Europe since 2004 by Servier as Protelos or Osseor[R], is the only prescription strontium-based therapy for the treatment of osteoporosis.
The reason for this is simple: Strontium ranelate is a drug patented by Servier Pharmaceuticals.
In the Treatment of Peripheral Osteoporosis (TROPOS) study, 5091 postmenopausal women (mean age, 77 years) with osteoporosis who were not receiving any antiosteoporosis medications were randomly assigned to receive, in double-blind fashion, 2 g per day of strontium ranelate (680 mg per day of elemental strontium) or placebo for five years.